The Role of FOXK2-FBXO32 in Breast Cancer Tumorigenesis: Insights into Ribosome-associated Pathways

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2024 Nov 18

PMID 39552461

Authors

Fuben Liao

Jinjin Zhu

Junju He

Zheming Liu

Yi Yao

Qibin Song

Affiliations

Soon will be listed here.

Abstract

Objective: To search for a new biomarker that can predict the efficacy and prognosis of tumor immunotherapy.

Method: FOXK2 genes were analyzed using single-cell sequencing in pan-cancer bulk RNA-seq from the TCGA database. We used algorithms to predict their immune infiltration. Functional enrichment and ChIP-seq identified potential downstream gene, FBXO32. FBXO32's role in cancer immune response was explored through analysis.

Results: Significant up-regulation of FOXK2 was observed in prostate adenocarcinoma (PRAD), uterine corpus endometrial carcinoma (UCEC), bladder urothelial carcinoma (BLCA), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and stomach adenocarcinoma (STAD), while no such increase was found in lung cancer (lung adenocarcinoma [LUAD], lung squamous cell carcinoma [LUSC]) or thyroid carcinoma (THCA) tumor and adjacent tissues. FOXK2 expression correlated with patient prognosis, with lower expression associated with better immune response and survival and higher expression of its downstream gene FBXO32 linked to worse overall survival (OS) and immune infiltration. FOXK2 has the potential to be used as a prognostic indicator and target for treatment in individuals with cancer.

Conclusion: Our research provides insights into the significance of FOXK2 in cancer and indicates its potential as both a prognostic indicator and target for treatment. The ribosome-associated pathways involving FOXK2 and FBXO32 could be pivotal in the advancement of tumors, offering possible avenues for targeted and individualized immunotherapy approaches. Additional research is required to completely understand the mechanisms that are responsible for the participation of FOXK2 and its subsequent gene FBXO32 in cancer, as well as to explore the possible advantages of focusing on FOXK2 for cancer treatment.

Citing Articles

The role of FOXK2-FBXO32 in breast cancer tumorigenesis: Insights into ribosome-associated pathways.

Liao F, Zhu J, He J, Liu Z, Yao Y, Song Q Thorac Cancer. 2024; 16(1):e15482.

PMID: 39552461 PMC: 11729401. DOI: 10.1111/1759-7714.15482.

References

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Liao F, Zhu J, He J, Liu Z, Yao Y, Song Q . The role of FOXK2-FBXO32 in breast cancer tumorigenesis: Insights into ribosome-associated pathways. Thorac Cancer. 2024; 16(1):e15482. PMC: 11729401. DOI: 10.1111/1759-7714.15482. View

Chen S, Jiang S, Hu F, Xu Y, Wang T, Mei Q . Foxk2 inhibits non-small cell lung cancer epithelial-mesenchymal transition and proliferation through the repression of different key target genes. Oncol Rep. 2017; 37(4):2335-2347. DOI: 10.3892/or.2017.5461. View

Kong J, Zhang Q, Liang X, Sun W . FOXK2 downregulation suppresses EMT in hepatocellular carcinoma. Open Med (Wars). 2020; 15(1):702-708. PMC: 7706124. DOI: 10.1515/med-2020-0129. View

Nestal de Moraes G, Carneiro L, Maia R, Lam E, Sharrocks A . FOXK2 Transcription Factor and Its Emerging Roles in Cancer. Cancers (Basel). 2019; 11(3). PMC: 6468357. DOI: 10.3390/cancers11030393. View

Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H . Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019; 11(1):34. PMC: 6534875. DOI: 10.1186/s13073-019-0638-6. View

Slyper M, Porter C, Ashenberg O, Waldman J, Drokhlyansky E, Wakiro I . A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020; 26(5):792-802. PMC: 7220853. DOI: 10.1038/s41591-020-0844-1. View

Tang Z, Kang B, Li C, Chen T, Zhang Z . GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019; 47(W1):W556-W560. PMC: 6602440. DOI: 10.1093/nar/gkz430. View

Shan L, Zhou X, Liu X, Wang Y, Su D, Hou Y . FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic Response and Breast Cancer Carcinogenesis. Cancer Cell. 2016; 30(5):708-722. DOI: 10.1016/j.ccell.2016.09.010. View

10.

Chen Y, Wu J, Liang G, Geng G, Zhao F, Yin P . CHK2-FOXK axis promotes transcriptional control of autophagy programs. Sci Adv. 2020; 6(1):eaax5819. PMC: 6938702. DOI: 10.1126/sciadv.aax5819. View

11.

Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann F . Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol. 2013; 31(19):2388-95. DOI: 10.1200/JCO.2012.44.3762. View

12.

Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M . Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013; 4:e838. PMC: 3824660. DOI: 10.1038/cddis.2013.350. View

13.

Chen F, Chandrashekar D, Varambally S, Creighton C . Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. 2019; 10(1):5679. PMC: 6908580. DOI: 10.1038/s41467-019-13528-0. View

14.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

15.

Thorvaldsdottir H, Robinson J, Mesirov J . Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2012; 14(2):178-92. PMC: 3603213. DOI: 10.1093/bib/bbs017. View

16.

Ellrott K, Bailey M, Saksena G, Covington K, Kandoth C, Stewart C . Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018; 6(3):271-281.e7. PMC: 6075717. DOI: 10.1016/j.cels.2018.03.002. View

17.

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

18.

Bowman C, Ayer D, Dynlacht B . Foxk proteins repress the initiation of starvation-induced atrophy and autophagy programs. Nat Cell Biol. 2014; 16(12):1202-14. PMC: 4250422. DOI: 10.1038/ncb3062. View

19.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

20.

Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M . Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2012; 328(2):198-206. DOI: 10.1016/j.canlet.2012.09.017. View